This Article Figures Only Full Text Full Text (PDF) View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Law, Y. M. Articles by Silberbach, M. Search for Related Content PubMed PubMed Citation Articles by Law, Y. M. Articles by Silberbach, M. Related Collections Related Articles

CLINICAL RESEARCH: BIOMARKERS

Accuracy of Plasma B-Type Natriuretic Peptide to Diagnose Significant Cardiovascular Disease in Children

The Better Not Pout Children! Study

Yuk M. Law, MD^_*,_*, Andrew W. Hoyer, MD, Mark D. Reller, MD and Michael Silberbach, MD

^_* Pediatric Cardiology, Department of Pediatrics, Children's Hospital and Regional Medical Center, University of Washington, Seattle, Washington
University of Virginia, Charlottesville, Virginia
Doernbecher Children's Hospital, Oregon Health & Science University, Portland, Oregon

Manuscript received December 16, 2008; revised manuscript received May 13, 2009, accepted June 2, 2009.

^_* Reprint requests and correspondence: Dr. Yuk M. Law, Children's Hospital and Regional Medical Center, University of Washington, 4800 Sand Point Way NE, M/S G-0035, Seattle, Washington 98105 (Email: yuk.law{at}seattlechildrens.org).

Objectives: The purpose of this study was to assess the ability of plasma B-type natriuretic peptide (BNP) to diagnose significant cardiovascular disease (CVD) in the pediatric population.

Background: BNP has been shown to be reliable in detecting ventricular dysfunction and heart failure in adults. Timely and accurate identification of significant pediatric heart disease is important but challenging. A simple blood test could aid the front-line physician in this task.

Methods: Subjects without a history of heart disease with findings possibly attributable to significant CVD in the acute care setting requiring a cardiology consult were enrolled. Clinicians were blinded to the BNP result, and confirmation of disease was made by cardiology consultation.

Results: Subjects were divided into a neonatal (n = 42, 0 to 7 days) and older age group (n = 58, >7 days to 19 years). CVD was present in 74% of neonates and 53% of the older age group. In neonates with disease, median BNP was 526 pg/ml versus 96 pg/ml (p < 0.001) for those without disease. In older children with disease, median BNP was 122 pg/ml versus 22 pg/ml in those without disease (p < 0.001). Subjects with disease from an anatomic defect, a longer hospital stay, or who died had higher BNP. A BNP of 170 pg/ml yielded a sensitivity of 94% and specificity of 73% in the neonatal group and 87% and 70% in the older age group, respectively, using a BNP of 41 pg/ml.

Conclusions: BNP is a reliable test to diagnose significant structural or functional CVD in children. Optimal cutoff values are different from adult values.

Key Words: B-type natriuretic peptide • cardiovascular disease • children • biomarkers • heart failure

Abbreviations and Acronyms   BNP = B-type natriuretic peptide   CVD = cardiovascular disease   CXR = chest X-ray   NPV = negative predictive value   PPV = positive predictive value

Related Articles

Decision Levels for Plasma B-Type Natriuretic Peptide Assay to Diagnose Significant Cardiovascular Disease in Children

Massimiliano Cantinotti, Simona Storti, Maura Crocetti, Nadia Assanta, Bruno Murzi, and Aldo Clerico
J. Am. Coll. Cardiol. 2010 55: 1166-1167. [Full Text] [PDF]

This article has been cited by other articles:

				S. E. G. Hamrick and G. Hansmann Patent Ductus Arteriosus of the Preterm Infant Pediatrics, May 1, 2010; 125(5): 1020 - 1030. [Abstract] [Full Text] [PDF]

				M. Cantinotti, S. Storti, M. Crocetti, N. Assanta, B. Murzi, and A. Clerico Decision Levels for Plasma B-Type Natriuretic Peptide Assay to Diagnose Significant Cardiovascular Disease in Children J. Am. Coll. Cardiol., March 16, 2010; 55(11): 1166 - 1167. [Full Text] [PDF]

				Y. M. Law, A. W. Hoyer, M. D. Reller, and M. Silberbach Reply. J. Am. Coll. Cardiol., March 16, 2010; 55(11): 1167 - 1167. [Full Text] [PDF]

				F. Locatelli and S. Vigano Are natriuretic peptides a reliable marker for mortality in ESRD patients? Nephrol. Dial. Transplant., February 1, 2010; 25(2): 347 - 349. [Full Text] [PDF]

				A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al. Highlights of the Year in JACC 2009 J. Am. Coll. Cardiol., January 26, 2010; 55(4): 380 - 407. [Full Text] [PDF]

				E. Madriago and M. Silberbach Heart Failure in Infants and Children Pediatr. Rev., January 1, 2010; 31(1): 4 - 12. [Full Text] [PDF]

				T. Socrates, N. Arenja, and C. Mueller B-Type Natriuretic Peptide in Children: Step by Step... J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1476 - 1477. [Full Text] [PDF]